Drug General Information |
Drug ID |
D0ZU5W
|
Former ID |
DNC010045
|
Drug Name |
1-(2-(benzyloxy)phenyl)piperazine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C17H20N2O
|
Canonical SMILES |
C1CN(CCN1)C2=CC=CC=C2OCC3=CC=CC=C3
|
InChI |
1S/C17H20N2O/c1-2-6-15(7-3-1)14-20-17-9-5-4-8-16(17)19-12-10-18-11-13-19/h1-9,18H,10-14H2
|
InChIKey |
PPQUPQGZDGZYJI-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Sodium-dependent noradrenaline transporter |
Target Info |
Inhibitor |
[1]
|
Sodium-dependent serotonin transporter |
Target Info |
Inhibitor |
[1]
|
5-hydroxytryptamine 1A receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Serotonergic synapsehsa04024:cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
Serotonergic synapse
|
NetPath Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesisP04373:5HT1 type receptor mediated signaling pathway
|
5HT2 type receptor mediated signaling pathway
|
5HT3 type receptor mediated signaling pathway
|
5HT4 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
5HT1 type receptor mediated signaling pathway
|
Reactome
|
Na+/Cl- dependent neurotransmitter transportersR-HSA-390666:Serotonin receptors
|
G alpha (i) signalling events
|
WikiPathways
|
Monoamine Transport
|
NRF2 pathway
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport
|
SIDS Susceptibility Pathways
|
Synaptic Vesicle Pathway
|
Serotonin Transporter ActivityWP722:Serotonin HTR1 Group and FOS Pathway
|
Monoamine GPCRs
|
GPCRs, Class A Rhodopsin-like
|
GPCR ligand binding
|
GPCR downstream signaling
|
References |
REF 1 | Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists. |